Last Updated: 09/03/2023
Host targeted adjunctive therapies to boost antimalarial immunity
Objectives
To investigate the ability of a repurposed drug to prevent the development of disruptive immune responses during malaria in humans.
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
Malaria caused 200 million cases and 400000 deaths in 2018. One problem in developing new control strategies for malaria is that following a malaria infection, individuals develop disruptive immune responses that block vaccines. Our project investigates the ability of a repurposed drug to prevent the development of disruptive immune responses during malaria in humans. Results of our studies will inform the development of new malaria control tools.
External reference
Thematic Categories
Date
Jan 2021 — Dec 2022
Total Project Funding
$1.52M
Funding Details
National Health and Medical Research Council (NHMRC) Australia, Australia
Grant number: 2002957
Project Site
Related Resources
